Listed by the USPTO as MOORE, SUSANNA
Tech Center 1600 • Art Units: 1624 1625 1626
This examiner grants 68% of resolved cases
MOORE, SUSANNA is a USPTO patent examiner in Tech Center 1600 and Art Unit 1624. The record includes 1268 resolved cases and an allowance rate of 68.0%. The median time to allowance is 1061 days. Interviews are associated with a 31.6% lift in allowance outcomes, providing a meaningful prosecution signal.
The leading companies are The Regents of the University of California, Globachem NV, and Sun Pharmaceutical Industries Ltd. The leading firms are OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., MH2 TECHNOLOGY LAW GROUP, LLP, and Apex Attorneys at Law, LLP. The substantial case history supports using the figures for portfolio planning. Practitioners can prioritize interview preparation where it may clarify claim distinctions, while accounting for the median timing in prosecution schedules.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18663097 | FLUORINATED PHTHALOCYANINE COMPOUND, COLORING COMPOSITION, AND INKJET INK | Non-Final OA | FUJIFILM CORPORATION |
| 18871590 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | Non-Final OA | Novartis AG |
| 17058390 | PRODRUGS OF FULVESTRANT | Final Rejection | KASHIV BIOSCIENCES, LLC |
| 18406937 | DINUCLEAR GOLD(I) COMPLEXES FOR TREATING CANCER | Final Rejection | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS |
| 18869346 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | Non-Final OA | The Johns Hopkins University |
| 17911388 | METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY THE PHYTOPATHOGENIC MICROORGANISM CORYNESPORA CASSIICOLA, CERCOSPORA SOJINA AND/OR CERCOSPORA KIKUCHII | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18283395 | ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | Non-Final OA | The Regents of the University of California |
| 17753902 | METHOD OF MAKING AND/OR ISOLATING ISOIDIDE, COMPRISING SELECTIVE ESTERIFICATION OF A MIXTURE OF DIANHYDROHEXITOL ISOMERS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17676211 | Compounds to Identify Beta-Lactamases, and Methods of Use Thereof | Final Rejection | The Regents of the University of California |
| 18715147 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Final Rejection | Vanderbilt University |
| 18905925 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Final Rejection | Sun Pharmaceutical Industries, Inc. |
| 18078571 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Final Rejection | Sun Pharmaceutical Industries, Inc. |
| 18038579 | ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES | Final Rejection | AMGEN INC. |
| 17758492 | TARGETED STEROID COMPOUNDS | Non-Final OA | Purdue Research Foundation |
| 18685194 | SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS | Final Rejection | University of Virginia Patent Foundation |
| 18366544 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18017000 | IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Final Rejection | The Trustees of Columbia University in the City of New York |
| 17912429 | COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGIC PAIN ASSOCIATED WITH MALIGNANT GROWTH DISORDER | Final Rejection | Duke University |
| 18262682 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | Non-Final OA | BIOVENTURES, LLC |
| 18293122 | METHODS FOR SYNTHESIS OF RACEMIC, SCALEMIC, AND CHIRAL ALPHA-TOCOTRIENOL QUINONE | Final Rejection | PTC Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy68.0% of resolved applications examined by Susanna Moore were allowed (1,268 resolved cases), compared with 54.6% across Art Unit 1624 over the last five years.
This examiner's interview lift is +31.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Susanna Moore took 1,061 days on average from filing to allowance.
Susanna Moore examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
